Banner

Serum Neprilysin Is a Significant Predictor of Metabolic Syndrome in Psoriasis Patients

Egyptian journal of hospital medicine • 2022
Back
Publication Information
Authors Essam Mohamed Akl;Nehad A. Fouad;Marwa Bashir Amir Alamin;Karem Taha Khalil
Keywords Psoriasis;Neprilysin;PASI; Metabolic syndrome
Journal Egyptian journal of hospital medicine
Publisher Not Available
Volume Not Available
Issue Not Available
Pages Not Available
publication.type Local
Paper Link Not Available
Supplementary Materials Not Available
Abstract
Background: There is a lot of disagreement on the connection between metabolic syndrome and psoriasis. A
membrane-bound metallopeptidase with a wide variety of physiological uses is neprilysin (NEP). New information
suggests that NEP may contribute to the aetiology of the metabolic syndrome.
Objective: To evaluate serum NEP levels and their significance in the metabolic features of psoriasis patients.
Patients and Methods: A total of fifty psoriasis patients and thirty healthy volunteers of matched age and sex
participated in this case-control research. Every participant underwent clinical examination with focus on measuring
the PASI score, blood pressure (systolic, SBP and diastolic, DBP), and abdominal circumference. Additionally, lipid
profile, NEP, and fasting blood sugar (FBS) assays were performed.
Results: In comparison to controls, psoriasis patients had significantly higher SBP, DBP, FBS, and triglycerides
(p=0.01, 0.04, 0.04, and 0.01, respectively). Median level of NEP was 225.35pg/mL with range of 45.4-540.2pg/mL in
psoriasis patients compared with controls (51.65, 41.6-368.9) (p